Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
By M. Krzystolik, Mehran A. Afshari, A. Adamis, J. Gaudreault, E. Gragoudas, N. Michaud, Wenjun Li, E. Connolly, Charles A. O’Neill, Joan W. Miller. A M A Archives of Ophthalmology, 2002
600 citations recorded by the source corpus.
Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/13e31fb4415a4d39a5b98339b548a5dfa11b84b9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Experimental data have also highlighted the critical role of VEGFA in non-ischaemic vascular disease, most importantly choroidal neovascularization 190,191 , which characterizes neovascular AMD, and diabetic blood–retina barrier breakdown 192 , the central pathology of diabetic macular oedema (DME).”
- Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex (2012, background): “Anti-VEGF therapies were able to inhibit the laser-induced CNV in animal models (Krzystolik et al., 2002; Saishin et al., 2003) and CNV in human AMD subjects (Jyothi et al.”
- Ranibizumab in neovascular age-related macular degeneration (2006, unknown): “Signifi cant prevention of CNV formation in susceptible animals and reduction of CNV activity expressed as angiographic leakage in those animals already harboring neovascularization was found (Krzystolik et al 2002).”
- The biology of VEGF and its receptors (2003, background): “Treatment with rhuFab VEGF reduces angiogenesis and vascular leakage in a primate model of AM”